William G. Kramer - Concepedia

Author

William G. Kramer

Also Known As

Kramer, William G., W G Kramer, W KRAMER, W Kramer, W Krámer, W. G. KRAMER, W. G. Kramer, W. KRAMER, W. Kramer, W.G. Kramer

155

Publications

3.7K

Citations

H-Index

110

Concepts

All Affiliations

Massanutten Regional Library University of Houston Roche (United States)Indiana University – Purdue University Indianapolis The Ohio State University

About

William G. Kramer is an author at Massanutten Regional Library specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	39	1.7K
2	Health Sciences	3	3	461
3	Engineering	1	1	20
4	Humanities	1	1	37
5	Natural Sciences	1	1	21

William G. Kramer

Publications

3.3K

Citations

H-Index

Page 1

	Year	Citations
Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure* Dennis Vargo, William G. Kramer, Paula Black, Clinical Pharmacology & Therapeutics	1995	299
Safety, Pharmacokinetics, and Effects on Cognitive Function of Multiple Doses of GTS-21 in Healthy, Male Volunteers Harumi KITAGAWA, Toshiharu TAKENOUCHI, Ryotaro Azuma, Neuropsychopharmacology Psychoactive DrugPsychiatryCognitive PerformanceMultiple DosesDementia	2002	234
Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study of ACE-011 (ActRIIA-IgG1) in Postmenopausal Women Jon Ruckle, Mark Jacobs, William G. Kramer, Journal of Bone and Mineral Research SclerostinGynecologyPharmacotherapyFc PortionOsteoporosis	2008	207
Pharmacokinetics of Amphotericin B in Infants and Children Jeffrey R. Starke, E. O. Mason, William G. Kramer, The Journal of Infectious Diseases Drug SafetyMedicineBioanalysisPediatricsAmphotericin B	1987	126
DEMOGRAPHIC FACTORS AFFECTING THE PHARMACOKINETICS OF CYCLOSPORINE ESTIMATED BY RADIOIMMUNOASSAY Barry D. Kahan, William G. Kramer, C A Wideman, Transplantation Therapeutic Drug MonitoringRenal FunctionPharmacokinetic ModelingLower CmaxPhysiologically-based Pharmacokinetic Modeling	1986	126
A Randomized Study of a Monoclonal Antibody (Pagibaximab) to Prevent Staphylococcal Sepsis Helen Thackray, Robin H. Steinhorn, William F. Walsh, PEDIATRICS	2011	95
Pharmacokinetics of digoxin: Comparison of a two- and a three-compartment model in man William G. Kramer, Richard P. Lewis, Tyson C. Cobb, Journal of Pharmacokinetics and Biopharmaceutics Molecular PharmacologyPharmacological StudyMedicinePhysiologyThree-compartment Model	1974	91
Phase 1/2 Double-Blind, Placebo-Controlled, Dose Escalation, Safety, and Pharmacokinetic Study of Pagibaximab (BSYX-A110), an Antistaphylococcal Monoclonal Antibody for the Prevention of Staphylococcal Bloodstream Infections, in Very-Low-Birth-Weight Neonates Leonard E. Weisman, Helen Thackray, Joseph A. Garcia‐Prats, Antimicrobial Agents and Chemotherapy	2009	86
Effect of cardiopulmonary bypass on fentanyl distribution and elimination Adolph J. Koska, Alexander Romagnoli, William G. Kramer Clinical Pharmacology & Therapeutics Cardiac AnaesthesiaAnesthetic PharmacologyFentanyl KineticsMedicinePharmacotherapy	1981	73
Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes Eric P. Hoffman, Valerie Riddle, Maxime A. Siegler, Steroids	2018	72

Page 1